Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 NovAliX Acquires Sanofi Site in Strasbourg | Contract Pharma

What are you searching for?

Sign in
Breaking News

NovAliX Acquires Sanofi Site in Strasbourg

Creates Guy Ourisson Research Campus boosting research capacity with plans to set up therapeutic innovation campus and center for cryo-electron microscopy.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

NovAliX, a Contract Research Organization (CRO) specializing in drug research and development, has acquired Sanofi’s 3.7 acre site, including a 86,000 sq.-ft. building designed to the highest standards for pharmaceutical research.
 
This represents the first stage in its development project that will allow it to offer clients a more complete, high-quality portfolio with enhanced biological and pharmacological services.
 
The site will be known as the Guy Ourisson Research Campus and will be shared by a number of users:
 
            •          NovAliX, with its main headquarters and scientific center for providing research services
            •          The Biophysics Institute for Biomedical Research (Institut de Biophysique pour la Recherche Biomédicale – IBRB), a center co-founded with an academic group, which focuses on medical innovation arising from advances in cryo-electron microscopy
            •          The Biotech Factory, comprised of laboratories dedicated to therapeutic innovation used by several biotechnology companies
 
“Our main goal was to find a buyer who could maintain very high standards of quality biomedical research. NovAliX ticked every box on our list,” said Jacques Volckmann, head of R&D France at Sanofi. “I’m delighted to see NovAliX further develop its activity in Strasbourg following this purchase and to see it become a key player in the local ecosystem with its international ambition. Sanofi will also benefit from the expertise of NovAliX’s teams – with a partnership announced at the end of 2021, through which we are currently working together to develop new DNA-encoded libraries.”
 
“By acquiring this site, NovAliX gets the chance to accelerate its development, make use of new biological and pharmacological capacity, and therefore strengthen its position as a CRO and become a vital and valuable partner, contributing to the success of its clients’ therapeutic research programs,” said Stephan Jenn, president and co-founder of NovAliX. “This transaction also represents an opportunity for the company founders to bring our vision of the future of research to life. This campus serves as a manifesto, it promises a new way of organizing discovery research and offers a one-stop location, bringing stakeholders together in order to foster the emergence and success of therapeutic innovation.”
 
The Biophysics Institute for Biomedical Research is a project that brings NovAliX together with a world-renowned academic group. It is not only a technological platform offering cryo-electron microscopy at the highest level, but also a location dedicated to creating new therapeutic options and technologies.
  
The construction program, led by Guillaume Delemazure from DeA architects, will commence in 2022 and transform the site at the campus; it will be appropriately kitted out for all the activity due to take place.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics